SSRI antidepressants

ApprovedSmall molecule

NNanjing Medical University

SSRI antidepressants is one of 70 small molecule programs targeting Panic Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Panic DisorderActive, not recruiting

Major Depressive DisorderActive, not recruiting

Panic DisorderPhase 2

Active, not recruiting

Major Depressive DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Daliresp

AstraZeneca

Phase 3

1 2

Risperdal

WWim Janssens

Phase 3

2 3

Fetzima

AbbVie

Phase 3

9 4

Desvenlafaxine SR

Pfizer

Phase 3

13 5

SPD489

Takeda

Phase 3

3 6

Venlafaxine ER

Pfizer

Phase 3

2 7

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

2 8

SSRI antidepressants

NNanjing Medical University

Approved

1 9

Antidepressant Therapy

AbbVie

Phase 3

4 10

Saredutant

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depressive Disorder1 trial

Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder

Unknown status·NNanjing Medical University·Phase 4·NCT01460212·80 enrolled

Panic Disorder1 trial

Different Neural Circuit Mechanisms Between Cognitive Therapy and Behavior Therapy for Patients With Panic Disorder: a Dynamic Research

Unknown status·NNanjing Medical University·Phase 2·NCT03199625·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SSRI antidepressants. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SSRI antidepressants compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SSRI antidepressants. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNanjing Medical University

SSRI antidepressants

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Major Depressive Disorder1 trial

Panic Disorder1 trial

References

Drug Info

Quick Facts

Related News